By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson and UCL Business, a subsidiary of University College London, announced this week an agreement that could lead to biomarker assays for ovarian and breast cancers.

The deal gives BD access to UCL's biobanks containing more than 200,000 human patient samples collected in prospective screening clinical trials for the detection and management of epithelial ovarian cancer. BD will use the samples to develop and validate biomarker assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.